Abstract 375P
Background
Perturbations in key driver genes or recurrently somatic mutated genes, as well as altered signaling pathways underlying pancreatic cancer have been largely discovered with the help of massive parallel sequencing. However, to date, the relationships between somatic alterations occurrence and clinical features are still less understood in pancreatic cancer.
Methods
Using the genomic DNA from each sample, libraries were constructed by shearing genomic DNA and ligating Illumina paired-end adaptors first, then the constructed libraries were hybridized to Agilent Human All Exon Target Enrichment kit V1. The purified capture products were then amplified to make whole exome libraries. The qualified libraries were subjected to 150 base paired-end sequencing on the Illumina NovaSeq instrument. The Genome Analysis Toolkit (GATK) was used to call variants in the sequencing data. All the statistical analyses were performed using IBM SPSS Statistics version 23.0 software.
Results
In this study, a total of 54 pancreatic ductal adenocarcinoma patients were enrolled, and pancreatic tumour samples without matched normal tissues were subjected to whole-exome sequencing. Based on the high-confidence putative somatic genes identified from our tumour-only sequencing, the results revealed alterations in cancer progression- and metastatic-related signaling pathways (i.e., E-cadherin and CDC42 signaling pathways) were predominantly enriched in late-stage (stage III/IV) tumours. Moreover, mutant EHMT1, as well as KRT6C, were significantly associated with tumour stage, while mutant H3F3A, DPY19L2, ABCB5, and ASTN1 were all significantly associated with the degree of tumour differentiation.
Conclusions
Together, our data suggest the prevalence of association between somatic alteration at the genomic level and clinical features in pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract